Targeting AKT and DNA-PK as a therapeutic strategy in platinum-resistant high-grade serous ovarian cancer

被引：0
|
作者：
Rinne, N. [1 ]
Curry, E. [1 ]
Fotopoulou, C. [1 ]
Gabra, H. [1 ,2 ]
Cunnea, P. [1 ]
机构：
[1] Imperial Coll London, Ovarian Canc Act Res Ctr, Dept Canc & Surg, London, England
[2] AstraZeneca, IMED Biotech Unit, Early Clin Dev, Cambridge, England
来源：
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 2019年 / 126卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
1985
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [31] Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
    Silva, Vera L.
    Saxena, Jayeta
    Nicolini, Francesco
    Hoare, Joseph, I
    Metcalf, Stephen
    Martin, Sarah A.
    Lockley, Michelle
    CELL DEATH & DISEASE, 2021, 12 (04)
  • [32] Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer
    Han, Xiaoyang
    Gao, Yan
    Jiang, Mei
    Li, Zhefeng
    Guo, Jiahao
    Li, Yue
    Yi, Junjie
    Hou, Lisha
    Cheng, Jin
    Feng, Lei
    Jin, Yulan
    Zhao, Xiaoting
    Yue, Wentao
    JOURNAL OF CANCER, 2024, 15 (11): : 3427 - 3440
  • [33] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Wong-Brown, Michelle W.
    van der Westhuizen, Andre
    Bowden, Nikola A.
    BMC CANCER, 2022, 22 (01)
  • [34] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [35] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Michelle W. Wong-Brown
    Andre van der Westhuizen
    Nikola A. Bowden
    BMC Cancer, 22
  • [36] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [37] Repurposing simvastatin to inhibit the mevalonate pathway as a therapeutic strategy to treat high-grade serous ovarian cancer
    Pereira, Madison
    Matuszewska, Kathy
    Haagsma, Jacob
    Glogova, Alice
    Shepherd, Trevor G.
    Petrik, Jim
    CANCER RESEARCH, 2022, 82 (12)
  • [38] Targeting c-MYC in Platinum-Resistant Ovarian Cancer
    Reyes-Gonzalez, Jeyshka M.
    Armaiz-Pena, Guillermo N.
    Mangala, Lingegowda S.
    Valiyeva, Fatma
    Ivan, Cristina
    Pradeep, Sunila
    Echevarria-Vargas, Ileabett M.
    Rivera-Reyes, Adrian
    Sood, Anil K.
    Vivas-Mejia, Pablo E.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2260 - 2269
  • [39] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [40] High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
    Lisio, Michael-Antony
    Fu, Lili
    Goyeneche, Alicia
    Gao, Zu-hua
    Telleria, Carlos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04)
12345